EA201270325A1 - Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10) - Google Patents

Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)

Info

Publication number
EA201270325A1
EA201270325A1 EA201270325A EA201270325A EA201270325A1 EA 201270325 A1 EA201270325 A1 EA 201270325A1 EA 201270325 A EA201270325 A EA 201270325A EA 201270325 A EA201270325 A EA 201270325A EA 201270325 A1 EA201270325 A1 EA 201270325A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
epimetabolic
coq10
staff
sarcoma
Prior art date
Application number
EA201270325A
Other languages
English (en)
Inventor
Рангапрасад Сарангараджан
Нивен Раджин Нараин
Джон Пэтрик Маккук
Original Assignee
Ситотех Лэбс, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ситотех Лэбс, Ллс filed Critical Ситотех Лэбс, Ллс
Publication of EA201270325A1 publication Critical patent/EA201270325A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

Описаны способы и композиции для лечения саркомы у людей с использованием эпиметаболической сдвигающей добавки, такой как кофермент Q10, структурного блока CoQ10, производного CoQ10, аналога CoQ10, метаболита CoQ10 или интермедиата пути биосинтеза кофермента. Также обеспечиваются способы для оценки эффективности лечения, диагностики и прогноза саркомы.
EA201270325A 2009-08-25 2010-08-25 Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10) EA201270325A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Publications (1)

Publication Number Publication Date
EA201270325A1 true EA201270325A1 (ru) 2012-11-30

Family

ID=43730801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270325A EA201270325A1 (ru) 2009-08-25 2010-08-25 Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)

Country Status (15)

Country Link
US (2) US20110064747A1 (ru)
EP (1) EP2470169A4 (ru)
JP (2) JP6159085B2 (ru)
KR (1) KR101572463B1 (ru)
CN (2) CN108245497A (ru)
AU (2) AU2010292532A1 (ru)
BR (1) BR112012004237A8 (ru)
CA (1) CA2772068C (ru)
CR (1) CR20120120A (ru)
EA (1) EA201270325A1 (ru)
IL (1) IL218306B (ru)
IN (1) IN2012DN01911A (ru)
MX (1) MX2012002208A (ru)
SG (2) SG178547A1 (ru)
WO (1) WO2011031503A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180056816A (ko) 2009-05-11 2018-05-29 베르그 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
CN110151591A (zh) 2012-10-09 2019-08-23 宝洁公司 鉴定协同化妆品组合的方法
US10302630B2 (en) 2012-10-09 2019-05-28 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
EP3567055A1 (en) * 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
MA52274A (fr) 2017-05-17 2021-02-24 Berg Llc Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
AU2022231043A1 (en) * 2021-03-05 2023-10-05 University Of Central Florida Research Foundation, Inc. Chaperonin-containing tcp-1 inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359816C (en) * 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
CA3031283A1 (en) * 2004-01-22 2005-08-04 University Of Miami Topical co-enzyme q10 formulations and methods of use
BRPI0511088A (pt) * 2004-05-14 2007-12-26 Monica Nister identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7910316B2 (en) * 2005-09-02 2011-03-22 Toray Industries, Inc. Kit and method for detecting urothelial cancer
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2642342A1 (en) * 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8030013B2 (en) * 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
EP2207038A4 (en) * 2007-10-18 2010-10-20 Medical Proteoscope Co Ltd PROCESS FOR POSTOPERATIVE FORECAST AND DIAGNOSIS KIT

Also Published As

Publication number Publication date
JP6159085B2 (ja) 2017-07-05
JP2016136938A (ja) 2016-08-04
JP2013503175A (ja) 2013-01-31
CA2772068C (en) 2017-03-21
IL218306A0 (en) 2012-04-30
US20130266557A1 (en) 2013-10-10
KR101572463B1 (ko) 2015-11-27
CA2772068A1 (en) 2011-03-17
IN2012DN01911A (ru) 2015-07-24
BR112012004237A8 (pt) 2016-10-04
WO2011031503A2 (en) 2011-03-17
SG10201405069QA (en) 2014-10-30
SG178547A1 (en) 2012-03-29
US20110064747A1 (en) 2011-03-17
WO2011031503A3 (en) 2011-07-21
CR20120120A (es) 2012-07-04
AU2016277749A1 (en) 2017-02-02
AU2010292532A1 (en) 2012-04-05
BR112012004237A2 (pt) 2016-04-05
KR20120050495A (ko) 2012-05-18
MX2012002208A (es) 2012-06-12
CN102548549A (zh) 2012-07-04
EP2470169A2 (en) 2012-07-04
CN108245497A (zh) 2018-07-06
EP2470169A4 (en) 2013-03-13
IL218306B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EA201270325A1 (ru) Способы лечения саркомы с использованием эпиметаболической сдвигающей добавки (кофермента q10)
AU2018236800B2 (en) DNA-PK inhibitors
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
TW201713640A (en) Bruton's tyrosine kinase inhibitors
EA201170227A1 (ru) Имидазолкарбоксамиды
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MA32508B1 (fr) Composes organiques
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EA200701995A1 (ru) Способы уменьшения кальцификации
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri